Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | SVP and General Counsel | April 01, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 50,000 · Balance 50,000 F1: Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, April 1, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, April 1, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-07-31 · Other · Disposed 7,215 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-07-31 · Disposition to issuer · Disposed 23,735 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU (a "Company RSU"). F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment equal to the product of the Closing Amount multiplied by the number of Shares subject to such Company RSU, without interest and subject to the withholding of applicable taxes, plus (ii) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2034-11-01 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-31 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2035-01-16 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-31 · Disposition to issuer · Disposed 28,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU (a "Company RSU").
F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment equal to the product of the Closing Amount multiplied by the number of Shares subject to such Company RSU, without interest and subject to the withholding of applicable taxes, plus (ii) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 21:42 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-039689 · tm2611148-2_4seq1.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, April 1, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:10 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001104659-26-002225 · tm262553-2_4seq1.xml · derivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · SVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-06 F1 · shares: This stock option was granted pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:22 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,000 | Not disclosed Strike: $6.97 | Not disclosed |
DisclosureSEC source: 0000950170-25-100643 · ownership.xml · derivative · entry 4 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires 2035-01-16 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:22 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $6.05 | Not disclosed |
DisclosureSEC source: 0000950170-25-100643 · ownership.xml · derivative · entry 3 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2034-11-01 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:22 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Disposition to issuerCommon Stock | 23,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-100643 · ownership.xml · nonDerivative · entry 2 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU (a "Company RSU"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment equal to the product of the Closing Amount multiplied by the number of Shares subject to such Company RSU, without interest and subject to the withholding of applicable taxes, plus (ii) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 15:22 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | OtherCommon Stock | 7,215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-100643 · ownership.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · price: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:02 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 79 | $9.22 | $728.38 |
DisclosureSEC source: 0001562180-25-005086 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,950 F1 · shares: On June 24, 2025, the reporting person vested 234 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:09 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 176 | $6.91 | $1,216.16 |
DisclosureSEC source: 0001562180-25-003111 · primarydocument.xml · nonDerivative · entry 2 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,029 Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:09 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantCommon Stock | 525 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003111 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,205 F1 · shares: On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 1,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 525 shares. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:36 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 79 | $8.21 | $648.59 |
DisclosureSEC source: 0001562180-25-002756 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,680 F1 · shares: On March 24, 2025, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:54 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 2,502 | $7.49 | $18,739.98 |
DisclosureSEC source: 0001562180-25-001614 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,759 F1 · shares: On February 24, 2025, the reporting person vested 7,500 shares of time-based restricted stock units (RSUs) granted on August 24, 2023 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 100% on February 24, 2025. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 21:26 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 251 | $7.18 | $1,802.18 |
DisclosureSEC source: 0001562180-25-001200 · primarydocument.xml · nonDerivative · entry 2 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,261 F2 · shares: On February 13, 2025, the reporting person vested 750 shares of time-based restricted stock units (RSUs) granted on February 13, 2024 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 21:26 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 376 | $7.18 | $2,699.68 |
DisclosureSEC source: 0001562180-25-001200 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,512 F1 · shares: On February 13, 2025, the reporting person vested 1,125 shares of time-based restricted stock units (RSUs) granted on February 13, 2023 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:12 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to buy) · Derivative | 28,000 | $0.00 Strike: $6.97 | $0.00 |
DisclosureSEC source: 0001562180-25-000438 · primarydocument.xml · derivative · entry 2 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2035-01-16 F2 · derivative.exercise_date: The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 7,000 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 21,000 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:12 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000438 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,888 F1 · shares: Consists of shares of common stock issuable under 14,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on January 16, 2026. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 21:11 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 79 | $5.48 | $432.92 |
DisclosureSEC source: 0001562180-24-008597 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,888 F1 · shares: On December 24, 2024, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 20:24 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001562180-24-007490 · primarydocument.xml · derivative · entry 2 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-10-31 F2 · derivative.exercise_date: The option was granted on November 1, 2024, pursuant to the Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on November 1, 2025, and the remainder vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 20:24 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007490 · primarydocument.xml · nonDerivative · entry 1 Shiferman Gregory L. · CIK 0002041689 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,967 F1 · shares: Consists of shares of Common Stock issuable under 5,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on November 1, 2025, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.